Ironwood Pharmaceuticals reported second quarter 2026 results, posting total revenue of $113 million and GAAP net income of $51 million, or $0.31 per share. U.S. LINZESS net sales reached $282 million, driven by mid-single digit prescription demand growth and improved net pricing. The company raised its full-year 2026 financial guidance, increasing LINZESS U.S. net sales expectations to $1.15–$1.20 billion, total revenue to $460–$485 million, and adjusted EBITDA to greater than $310 million. Ironwood repaid the full $200 million principal amount of its convertible senior notes using cash on hand. Additionally, the company initiated the confirmatory Phase 3 STARS-2 trial for apraglutide in short bowel syndrome with intestinal failure and appointed Dr. Jeffrey Silber as chief medical officer.

Ironwood Pharmaceuticals, Inc. repaid the $200.0 million aggregate principal amount of its 1.50% convertible senior notes due 2026 at their scheduled maturity on June 15, 2026. The repayment was funded using available cash on hand, and no conversions were exercised by noteholders. Ironwood Pharmaceuticals, Inc. is a pharmaceutical company that develops and commercializes specialty medicine products.